|
1)日本集中治療医学会Sepsis Registry委員会(編):日本版敗血症診療ガイドライン.日集中医誌20:124-173,2013
|
|
|
|
2)Wang Y, Liu Y, Sarker KP et al:Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470:151-155, 2000
|
|
|
|
|
3)Abe S, Seo Y, Hayashi H et al:Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia;a pilot study. Blood Purif 29:321-326, 2010
|
|
|
|
|
|
4)Vincent JL, Laterre PF, Cohen J et al:A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400-405, 2005
|
|
|
|
|
|
5)Cruz DN, Antonelli M, Fumagalli R et al:Early use of polymyxin B hemoperfusion in abdominal septic shock;the EUPHAS randomized controlled trial.JAMA 301:2445-2452, 2009
|
|
|
|
|
|
6)Payen DM, Guilhot J, Launey Y et al:Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis;a multicenter randomized control trial. Intensive Care Med 41:975-984, 2015
|
|
|
|
|
|
7)Zhou F, Peng Z, Murugan R et al:Blood purification and mortality in sepsis;a meta-analysis of randomized trials. Crit Care Med 41:2209-2220, 2013
|
|
|
|
|
|
8)Iwagami M, Yasunaga H, Doi K et al:Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock;a propensity-matched analysis. Crit Care Med 42:1187-1193, 2014
|
|
|
|
|
|
9)Iwagami M, Yasunaga H, Noiri E et al:Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy;a propensity-matched analysis. Blood Purification 42:9-17, 2016
|
|
|
|
|
|
10)Klein DJ, Foster D, Schorr CA et al:The EUPHRATES trial(evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock);study protocol for a randomized controlled trial. Trials 15:218, 2014
|
|
|
|
|
|
11)Hotchkiss RS, Coopersmith CM, McDunn JE et al:The sepsis seesaw;tilting toward immunosuppression. Nat Med 15:496-497, 2009
|
|
|
|
|
|
12)Frazier WJ, Hall MW:Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am 55:647-xi, 2008
|
|
|
|
|
|
13)中田孝明, 織田成人,松田兼一ほか:重症敗血症に対するPMMA-CHDFによる治療戦略.日腹部救急医会誌29:739-745,2009
|
|
|
|
|
|
14)篠崎正博,中 敏夫,森永俊彦:急性血液浄化法の現状と展望─特に高サイトカイン血症に対する適応に関して.日集中医会誌5:357-363,1998
|
|
|
|
|
|
15)Thomas M, Moriyama K, Ledebo I:AN69:Evolution of the world's first high permeability membrane. Contrib Nephrol 173:119-129, 2011
|
|
|
|
|
|
16)Yumoto M, Nishida O, Moriyama K et al:In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial 15:385-393, 2011
|
|
|
|
|
|
17)Shiga H, Hirasawa H, Nishida O et al:Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock;a preliminary report. Blood Purif 38:211-218, 2014
|
|
|
|
|